ライフサイエンスコーパス: ICD

1 ICD can be induced by treatment with chemotherapeutics.

2 ICD has been predicted theoretically in the mid nineties

3 ICD is studied mainly in the context of regulated cell d

4 ICD use was associated with a reduction in all-cause mor

5 ICD was implanted 30 to 60 days after MI.

6 1 (43.0%) patients presented with at least 1 ICD complication, including inappropriate shocks in 42 (

7 After matching, 1305 ICD recipients were compared with 1305 nonrecipients.

8 Inpatients were identified using COVID-19 ICD-10-CM diagnosis codes.

9 shocks for VT) and deferred ablation after 3 ICD shocks for VT.

10 n assay, the interaction between MBP-5HT(3A)-ICD constructs and RIC-3 was investigated.

11 ant for the interaction between the 5-HT(3A)-ICD and RIC-3.

12 a 24-amino-acid-long segment of the 5-HT(3A)-ICD as a molecular determinant for the interaction betwe

13 n, we developed different MBP-fused 5-HT(3A)-ICD constructs by deleting large segments of its amino a

14 Additionally, we have shown that 5-HT(3A)-ICD fused to maltose-binding protein (MBP) directly inte

15 usly, we have demonstrated that the 5-HT(3A)-ICD is required for the interaction between 5-HT(3A) and

16 Cardiac devices included pacemakers (46%), ICDs (30%), cardiac resynchronization therapy (CRT) pace

17 TreeWAS analysis, examining 10,750 ICD-10 diagnostic terms, identified more sub-phenotypes

18 patients with ischemic heart disease, after ICD shock HCM patients rarely experience transformation

19 Patients with tetralogy of Fallot and an ICD experience high rates of appropriate therapies, incl

20 Substance misuse outcomes were defined as an ICD code of substance use-related disorder or cause of d

21 in which patients with an indication for an ICD but no indication for pacing were assigned to receiv

22 In patients with an indication for an ICD but no indication for pacing, the subcutaneous ICD w

23 ession analyses, we found that having had an ICD shock (OR, 2.05; CI, 1.64-2.56), having high levels

24 In an ICD process, energy released by electronic relaxation of

25 ed >=18 years who underwent an implant of an ICD between April 1, 2011 and March 31, 2016 were includ

26 reticulin and HMGB-1 and the induction of an ICD gene program.

27 al payment to the physician who performed an ICD or CRT-D implantation than each other manufacturer i

28 ers' payments to physicians who performed an ICD or CRT-D implantation.

29 sitive for influenza, 77% did not receive an ICD-CM diagnostic code for influenza.

30 Among 80 patients who received an ICD, 25 adverse events related to ICD implantation occur

31 to electrophysiology, 536 (27%) received an ICD, and 445 (23%) died.

32 temporary ICD leads in patients receiving an ICD system for the first time.

33 affect survival, whereas randomization to an ICD significantly decreased all-cause mortality by 23%.

34 he concept of in situ vaccination whereby an ICD inducing drug is injected locally to generate immuno

35 ll patients with tetralogy of Fallot with an ICD was initiated in 2010 by the French Institute of Hea

36 ional Classification of Diseases (ICD)-9 and ICD-10 codes documented in electronic medical records.

37 glycemia or hyperglycemia using ICD-9-CM and ICD-10-CM diagnostic codes.

38 ic diagnostic categories included in DSM and ICD are actually discrete disease entities.

39 , Ninth Revision, Clinical Modification, and ICD, 10th Revision.

40 ol significantly increased VT recurrence and ICD shocks compared with amiodarone.

41 Appropriate ICD therapy occurred in 9 patients at 3 years follow-up

42 3%) patients received at least 1 appropriate ICD therapy.

43 39.7% versus 48.2%; P=0.050) and appropriate ICD therapy (34.2% versus 47.0%; P=0.020) were numerical

44 ventricular tachyarrhythmia and appropriate ICD therapy.

45 e from ICD implantation to first appropriate ICD therapy.

46 he only independent predictor of appropriate ICD therapies (hazard ratio, 3.47 [95% CI, 1.19-10.11]),

47 y prevention, the annual rate of appropriate ICD therapies was 4.1%, 5.3%, 9.5%, and 13.3% in patient

48 te medical record abstractions and available ICD codes (median age, 69 years [interquartile range, 54

49 od should be related to the expected average ICD in normal eyes.

50 Preventive VT ablation before ICD implantation did not reduce mortality or hospitaliza

51 of preventive VT ablation (undertaken before ICD implantation to prevent ICD shocks for VT) and defer

52 ion of a soluble intracellular domain, beta1-ICD, which modulates transcription.

53 udy, we investigated the association between ICD diagnoses of TS/CTD and substance misuse outcomes, a

54 We investigated the association between ICD use and all-cause mortality in a contemporary heart

55 death regression model to jointly model both ICD shocks and death under the semi-competing risks fram

56 nia (ACP), and otitis media (OM), defined by ICD-10-AM codes, and to explore the effect by ethnicity

57 ute cardiovascular events were identified by ICD discharge codes and may be subject to misclassificat

58 ntaneous bacterial peritonitis identified by ICD-9/CPT codes.

59 nystagmus, or retinopathy of prematurity) by ICD-9 codes in typically developing (TD) controls and ch

60 the PD-L1 locus containing a consensus CD44-ICD binding site.

61 hancement of CD44-intracellular domain (CD44-ICD) production plays an important role in the de-differ

62 electroporated with a plasmid encoding CD44-ICD.

63 antable Cardioverter Defibrillators (EU-CERT-ICD), a prospective, investigator-initiated, non-randomi

64 rs can search for one or more disease codes (ICD-10 classification) and explore disease progression p

65 ized, multicenter, controlled trial compared ICD versus conventional medical therapy in high-risk pat

66 stry was performed evaluating 4 contemporary ICD leads in patients receiving an ICD system for the fi

67 the IAS rate in a more typical, contemporary ICD patient population implanted with the S-ICD using st

68 tributed to increased neurogenesis by CX3CL1-ICD, as revealed by morphological and unbiased RNA-seque

69 Immunogenic cell death (ICD) and tumour-infiltrating T lymphocytes are severely

70 e and induces robust immunogenic cell death (ICD) in cancer cells as characterized by multiple damage

71 tically, MFP induced immunogenic cell death (ICD) in vivo and in vitro, as depicted by the expression

72 deliver a potential immunogenic cell death (ICD) inducing agent, 17-(allylamino)-17-demethoxygeldana

73 Immunogenic cell death (ICD) is a way of reengaging the tumor-specific immune sy

74 Immunogenic cell death (ICD) occurs when a dying cell releases cytokines and dam

75 duced as a result of immunogenic cell death (ICD), are known to be a potential source of cancer vacci

76 cell death, known as immunogenic cell death (ICD), can propagate antitumoral immunity to augment ther

77 Immunogenic cell death (ICD)-inducing modalities not only directly kill cancer c

78 teratomic or intermolecular Coulombic decay (ICD) is a nonlocal electronic decay mechanism occurring

79 h an implantable cardioverter defibrillator (ICD) had tachycardia therapies disabled during the MRI.

80 ctic implantable cardioverter defibrillator (ICD) implantation in early selected high-risk patients a

81 the implantable cardioverter defibrillator (ICD) in this patient population remain scarce.

82 ored implantable cardioverter-defibrillator (ICD) electrograms.

83 from implantable cardioverter-defibrillator (ICD) implantation.

84 oing implantable cardioverter-defibrillator (ICD) implantations have high rates of long-term device-r

85 The implantable cardioverter-defibrillator (ICD) is effective for preventing sudden death in patient

86 (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden cardiac death prev

87 and Implantable Cardioverter-Defibrillator (ICD) Registry.

88 iate implantable cardioverter-defibrillator (ICD) therapy terminating potentially lethal tachyarrhyth

89 , or implantable cardioverter-defibrillator (ICD) therapy.

90 eous implantable cardioverter-defibrillator (ICD) was designed to avoid complications related to the

91 ith implantable cardioverter-defibrillators (ICDs).

92 ing implantable cardioverter-defibrillators (ICDs).

93 Isothermal chemical denaturation (ICD) can be applied to determine chemical stability, aim

94 Intercalated discs (ICD), specific cell-to-cell contacts that connect adjace

95 and International Classification of Disease (ICD)-9/10 codes.

96 on International classification of disease (ICD-10) criteria.

97 of International Classification of Diseases (ICD) codes with potential for improved specificity in cl

98 he International Classification of Diseases (ICD), Ninth Revision, Clinical Modification, and ICD, 10

99 om International Classification of Diseases (ICD)-9 and ICD-10 codes documented in electronic medical

100 he International Classification of Diseases (ICD-10) for cirrhosis or its complications.

101 on international classification of diseases [ICD]-10 coding) and deaths were obtained from NHS Digita

102 nd K(ATP) channels to the intercalated disk (ICD) of cardiomyocytes.

103 r (DSM-5) and of conduct-dissocial disorder (ICD-11) to designate those with elevated callous-unemoti

104 tion, the measured intercapillary distances (ICDs) should be consistent with known measurements using

105 ents indicate that the intracellular domain (ICD) of HyFatl affects actin organization through prolin

106 alpha3GlyRs within the intracellular domain (ICD), which decrease the GlyR-associated currents and en

107 ansmembrane (TMD), and intracellular domain (ICD).

108 through its cleaved intracytoplasmic domain (ICD), which bound to a regulatory region of the PD-L1 lo

109 In this regard, RTK intracellular domains (ICD) are of interest due to their ability to recapitulat

110 e also found that the intracellular domains (ICDs) of DSCAM and DSCAML1 specifically and directly int

111 The DSCAM ICD is released by gamma-secretase-dependent cleavage, a

112 he levels of either the DSCAM or the DSCAML1 ICD leads to an impairment of neurite growth.

113 ent cleavage, and both the DSCAM and DSCAML1 ICDs efficiently translocate to the nucleus.

114 pression of the DSCAM as well as the DSCAML1 ICDs alone can profoundly alter the expression of genes

115 hology, as exemplified by psychodynamic, DSM/ICD, and HiTOP paradigms.

116 : 66.5%, 78.5%, and 83.3% for ICD-9, "early" ICD-10, and "late" ICD-10, respectively.

117 ional Classification of Disease-9th edition (ICD-9) codes.

118 onal Classification of Diseases 9th edition (ICD-9) procedure codes or Current Procedural Terminology

119 Mutations in genes encoding ICD components are linked to cardiovascular diseases.

120 val for the 4 most commonly used high-energy ICD leads.

121 We expressed seven engineered ICDs in Escherichia coli and purified them to homogeneit

122 tment modalities that can induce and enhance ICD to potentiate cancer immunotherapy.

123 Proteomic analysis revealed that EphA3 ICD binds to non-muscle myosin IIA (NMIIA) and increases

124 -membrane translocation approach, where FGFR ICD is recruited from the cytoplasm to the plasma membra

125 eased with time: 66.5%, 78.5%, and 83.3% for ICD-9, "early" ICD-10, and "late" ICD-10, respectively.

126 receive a BPA recommending consideration for ICD implantation.

127 ioural, and neurodevelopmental disorders for ICD-11.

128 cause hospitalizations, hospitalizations for ICD shocks, and number and frequency of ICD shocks or an

129 Overall, predictive performance for ICD shock and death individually was adequate, based on

130 reased accuracy emphasizes the potential for ICD-10 coding to be used effectively in database researc

131 ry time to event end point was the time from ICD implantation to first appropriate ICD therapy.

132 andin E(2) blockade as a strategy to harness ICD.

133 ore, depressed patients faced an even higher ICD risk when receiving dopamine agonists.

134 syndrome (ICD-10 code Q90) and hypertension (ICD-10 code I10).

135 environment to relieve the immunosuppressive ICD elicited by specific chemotherapy and prolong the su

136 yopathy, after a primary prevention implant, ICD therapy often followed prolonged periods of device d

137 term safety of the 4 most commonly implanted ICD leads within the National Cardiovascular Data Regist

138 n performance and complications of implanted ICDs over particularly long time periods to inform clini

139 Coding in ICD-10 is more accurate than in ICD-9, particularly for

140 A meaningful difference in ICD failure rate was defined as twice (or more) the lead

141 Coding in ICD-10 is more accurate than in ICD-9, particularly for PDR compared with NPDR.

142 tantly, the murine cancer cell lines used in ICD studies often express virally derived peptides that

143 Inappropriate ICD shocks in 39 patients occurred most commonly <5 year

144 Secondary outcomes included ICD-related complications, heart transplantation, and de

145 2016 were prospectively collected, including ICD-10 diagnostic codes and OPCS-4 procedure codes.

146 contemporary treatment strategies, including ICDs and heart transplant, are associated with significa

147 was associated with significantly increased ICD shocks (HR=2.70 [95% CrI=1.17-6.71]).

148 identify physicians who performed >=10 index ICDs from 2006 to 2009.

149 70, and HMGB1); however, is unable to induce ICD.

150 could determine the outcome of drug-induced ICD and pose COX-2/prostaglandin E(2) blockade as a stra

151 u(I) bis-N-heterocyclic carbene that induces ICD both in vitro and in vivo.

152 Notably, Jag1-ICD promoted tumor growth and epithelial-mesenchymal tra

153 nical Notch activation and suggest that Jag1-ICD may behave as an oncogenic driver that is able to su

154 0.0001) times greater for "early" and "late" ICD-10 codes compared with ICD-9 codes, respectively.

155 83.3% for ICD-9, "early" ICD-10, and "late" ICD-10, respectively.

156 ases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes during 2016-2017 for blastomy

157 ases, Tenth Revision, Clinical Modification (ICD-10-CM), codes (379.21, 379.22, 379.24, and 379.25),

158 ases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases,

159 h life-threatening arrhythmias necessitating ICD implantation, we compared outcomes of preventive VT

160 mong the 374 132 patients who received a new ICD implant, no safety alerts were triggered for the pri

161 The considerable long-term burden of ICD-related complications, however, underlines the need

162 it the biomarker responses characteristic of ICD and to provide an anticancer benefit in vivo.

163 ined IDU-IE using a validated combination of ICD-9 codes.

164 the background population; the composite of ICD implantation, ventricular arrhythmias, and cardiac a

165 heoretical approaches for the description of ICD as well as the experimental techniques developed and

166 ical effectiveness and cost-effectiveness of ICD therapy.

167 for ICD shocks, and number and frequency of ICD shocks or anti-tachycardia pacing therapy.

168 Currently, the molecular hallmark of ICD features the release of damage-associated molecular

169 1; CI, 1.04-1.92), and having high levels of ICD concerns (OR, 1.53; CI, 1.22-1.92) were the only sig

170 The majority of ICD discharges occurred >=5 years after implant (29 pati

171 The proportion of ICD codes in agreement with the documented standard diag

172 cross-sectional study, a large proportion of ICD or CRT-D implantations were performed by physicians

173 ere no meaningful differences in the rate of ICD high-energy lead survival for the 4 most commonly us

174 e on experimental and theoretical studies of ICD processes in different atomic and molecular systems

175 ive claims data to describe trends in use of ICD-10-CM diagnosis codes for novel coronavirus patients

176 of Xinbeta, a newly-identified component of ICDs, results in cardiomyocyte proliferation defects and

177 nificantly predicted the treatment effect of ICDs on mortality (adjusted p=0.0307).

178 isation dynamics and the treatment effect of ICDs on mortality.

179 rial (Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure

180 associated with prophylactic implantation of ICDs in contemporarily treated patients with ischaemic o

181 ria for primary prophylactic implantation of ICDs.

182 itis at Howard University Hospital, based on ICD-10 code.

183 renorrhaphy, or endovascular repair based on ICD-9 procedure code.

184 studied the effect of baseline depression on ICD risk.

185 We relied on ICD-10 codes to identify hospital admissions with CVEs,

186 ational Classification of Diseases-Oncology (ICD-O) site and morphology codes.

187 omy surgery linked to one of the ICD-9-CM or ICD-10-CM codes for vitreous opacities were identified.

188 utics, SCNPs cause immunogenic cell death or ICD.

189 based on liver biopsy, abdominal imaging or ICD-coding and the absence of other liver diseases.

190 lent were used to define a diagnosis of OSA (ICD-9 327.23) and a diagnosis of XFS (ICD-9 365.52 and 3

191 ghlights necroptosis as a possible preferred ICD form over apoptosis in the treatment of cancer.

192 ndertaken before ICD implantation to prevent ICD shocks for VT) and deferred ablation after 3 ICD sho

193 f Cardiology criteria for primary-prevention ICD were included.

194 diomyopathy patients with primary prevention ICDs implanted before 2008 and followed for >=10 years (

195 Primary prevention ICDs should be considered when EF is <50% in HCM.

196 d alive between 2009 to 2017 without a prior ICD, were followed up to 90 days.

197 ylaxis and therefore in assigning the proper ICD-10 code.

198 powered randomized trial, early prophylactic ICD implantation demonstrated lower total and cardiac mo

199 I(KATP) functionally co-localize at the rat ICD, but not at the lateral membrane.

200 Patients were more likely to receive ICD or CRT-D devices from the manufacturer that provided

201 patient their probability of having received ICD shocks, dying, or both at any given point in time.

202 (median age, 65 years; 29.6% women) received ICD or CRT-D devices from the 4 manufacturers implanted

203 ) were associated with significantly reduced ICD shocks.

204 e end points of electrophysiology referrals, ICD implantations, and all-cause mortality.

205 om the National Cardiovascular Data Registry ICD Registry was linked with the Open Payments Program's

206 om the National Cardiovascular Data Registry ICD Registry with Medicare fee-for-service claims to ide

207 in the National Cardiovascular Data Registry ICD Registry.

208 al Classification of Diseases 10th revision (ICD-10) code M30.3 in the inpatient setting.

209 l Classification of Diseases, 10th Revision (ICD-10) diagnosis codes.

210 l Classification of Diseases, 10th revision (ICD-10), diagnosis of substance use disorder (codes F10.

211 al Classification of Diseases 10th Revision (ICD-10), there was a marked increase in the complexity o

212 onal Classification of Disease 9th revision (ICD)-9 code-based algorithms.

213 nal Classification of Diseases 9th revision (ICD-9) code 446.1 or International Classification of Dis

214 nal Classification of Diseases 9th Revision (ICD-9) transitioned to the International Classification

215 Classification of Diseases, Ninth Revision (ICD-9) codes or their Tenth Revision equivalent were use

216 Classification of Diseases, Ninth Revision (ICD-9) codes.

217 Classification of Diseases, Ninth Revision (ICD-9) diagnosis of endocarditis.

218 Classification of Diseases, Ninth Revision (ICD-9)/Current Procedures Terminology (CPT) codes.

219 Classification of Diseases, Tenth Revision (ICD-10).

220 involves membrane tethering of dimerizer-RTK ICD fusions.

221 S-ICD implant was attempted in 1116 patients, and 1111 pat

222 Generation 2 or 3 S-ICD devices were implanted and programmed with rate-base

223 high efficacy and safety with contemporary S-ICD devices and programming despite the relatively high

224 f comorbidities in comparison with earlier S-ICD trials.

225 However, patients in previous S-ICD studies had fewer comorbidities, had less left ventr

226 at 1 year) is the lowest reported for the S-ICD and lower than many transvenous ICD studies using co

227 HED trial (Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fra

228 ICD patient population implanted with the S-ICD using standardized programming and enhanced discrimi

229 cing were assigned to receive a subcutaneous ICD or transvenous ICD.

230 interval for the hazard ratio (subcutaneous ICD vs. transvenous ICD) was 1.45.

231 tal of 849 patients (426 in the subcutaneous ICD group and 423 in the transvenous ICD group) were inc

232 occurred in 31 patients in the subcutaneous ICD group and in 44 in the transvenous ICD group (hazard

233 occurred in 83 patients in the subcutaneous ICD group and in 68 in the transvenous ICD group (hazard

234 occurred in 68 patients in the subcutaneous ICD group and in 68 patients in the transvenous ICD grou

235 t no indication for pacing, the subcutaneous ICD was noninferior to the transvenous ICD with respect

236 y exploring multimorbidity in Down syndrome (ICD-10 code Q90) and hypertension (ICD-10 code I10).

237 andard and diagnostic classification system, ICD-11 will be highly influential by informing policy, c

238 Subgroup analysis revealed long-term ICD benefit varied according to HF etiology and New York

239 cal method was developed to identify all the ICD-10 codes related to anaphylaxis deaths, which were d

240 he basis of intention-to-treat analysis, the ICD group had overall survival benefit versus placebo dr

241 h other and to AnkG, but not to AnkB, at the ICD.

242 was the proportion of agreement between the ICD code and the documented chart standard for stage of

243 there was substantial agreement between the ICD codes for stage of DR and the documented standard (k

244 mance goal, derived from the results for the ICD-only patients in the MADIT-RIT study (Multicenter Au

245 cause mortality was significant lower in the ICD group (5% versus 13%, hazard ratio, 0.37 [95% CI, 0.

246 , 99 of 188 patients died (52.7%), 52 in the ICD group and 47 in the control group.

247 ility was 50.6% (95% CI, 39.8%-61.5%) in the ICD group and 54.5% (95% CI, 43.0-66.0%) in the control

248 5 years was 9.7% (95% CI, 3.3%-16.2%) in the ICD group and 7.9% (95% CI, 1.7-14.0%) in the control gr

249 s after inclusion of 188 patients, 97 in the ICD group and 91 in the control group.

250 CI, 0.28-0.99]) was significant lower in the ICD group.

251 All patients in the ICD Registry aged >=18 years who underwent an implant of

252 time from randomization, attenuation of the ICD benefit was observed after 6 years (p value for the

253 es ascertainment, active surveillance of the ICD Registry suggests that there were no meaningful diff

254 propensity-matched survival analysis of the ICD Registry was performed evaluating 4 contemporary ICD

255 that post-translational modifications of the ICD, such as phosphorylation, may shape the conductance

256 at an accessible lay language version of the ICD-11 could be beneficial for service users and their s

257 went vitrectomy surgery linked to one of the ICD-9-CM or ICD-10-CM codes for vitreous opacities were

258 d thirty-one patients were randomized to the ICD arm and 135 patients to the control arm.

259 e Hippo-YAP pathway by recruiting NF2 to the ICD to modulate cardiac function.

260 ing of both Na(+) and K(ATP) channels to the ICD, but not to lateral membranes.

261 kophilin2 and connexin 43 recruitment to the ICD.

262 in the complete Danish population using the ICD-10 and Global Burden of Disease terminologies.

263 VT recurred in 5 patients (15%) in whom the ICD-electrogram-guided approach was performed and in 13

264 medical center, only 2% of patients with the ICD-9/10 code for EC likely have the disease.

265 with a negatively charged residue within the ICD of alpha3GlyRs and of chimeric receptors combining b

266 al study, patients who received a first-time ICD or CRT-D device from any of the 4 major manufacturer

267 This review provides an introduction to ICD and draws the connection to related energy transfer

268 001), which was also independently linked to ICD development (HR = 1.87, 95% CI = 1.3-2.7, p < 0.001)

269 schemic systolic heart failure randomized to ICD or control underwent cardiovascular magnetic resonan

270 eceived an ICD, 25 adverse events related to ICD implantation occurred.

271 or the S-ICD and lower than many transvenous ICD studies using contemporary programming to reduce IAS

272 to receive a subcutaneous ICD or transvenous ICD.

273 group and in 68 patients in the transvenous ICD group (48-month Kaplan-Meier estimated cumulative in

274 neous ICD group and in 44 in the transvenous ICD group (hazard ratio, 0.69; 95% CI, 0.44 to 1.09); in

275 neous ICD group and in 68 in the transvenous ICD group (hazard ratio, 1.23; 95% CI, 0.89 to 1.70); ap

276 taneous ICD group and 423 in the transvenous ICD group) were included in the analyses.

277 oid complications related to the transvenous ICD lead by using an entirely extrathoracic placement.

278 neous ICD was noninferior to the transvenous ICD with respect to device-related complications and ina

279 ate shocks (IAS) than in typical transvenous ICD trials.

280 zard ratio (subcutaneous ICD vs. transvenous ICD) was 1.45.

281 diabetic eye disease was determined by using ICD-9 codes.

282 diagnosis for an ophthalmic condition using ICD-9-CM codes.

283 ALF was diagnosed using ICD-10 codes K72.0 and K71.11.

284 serious hypoglycemia or hyperglycemia using ICD-9-CM and ICD-10-CM diagnostic codes.

285 ary 22 to May 4, 2020, were identified using ICD-10 codes and followed up from day of diagnosis to ou

286 nts, we matched two controlled vocabularies (ICD-10 and a custom vocabulary developed at the clinical

287 Compared with patients whose ICDs were implanted by electrophysiologists, patients wi

288 Monitoring of safety began with ICD implant and continued up to 5 years.

289 early" and "late" ICD-10 codes compared with ICD-9 codes, respectively.

290 creatitis (physician-assigned diagnosis with ICD-10 code K85) occurring in the 90 days following trea

291 the management of this complex disease with ICD therapy responsible for a substantial decrease in ov

292 Conclusions Patients with ICD implantations performed by electrophysiologists had

293 antiarrhythmic drugs and CA in patients with ICD was conducted.

294 den death events among the 217 patients with ICD.

295 hicago-wide database of medical records with ICD-9 codes of cirrhosis and without a history of hepato

296 -related patterns of long-term survival with ICD benefit most evident at 11 years for ischemic HF pat

297 evices, in pacemaker-dependent patients with ICDs, and in patients with abandoned leads.

298 umber of HCM patients required to treat with ICDs to save 1 patient with abolition of lethal ventricu

299 Initiative, we included PD patients without ICDs at baseline according to the Questionnaire for Impu

300 f OSA (ICD-9 327.23) and a diagnosis of XFS (ICD-9 365.52 and 366.11).